SLC2A1 and neoplasm: [164] For example, a metabolic nanoregulator (D/B/CQ@ZIF‐8@CS) encapsulating antiglycolytic agent 2‐DG, GLUT1 inhibitor BAY‐876, and autophagy inhibitor chloroquine (CQ) was developed for synergetic tumor metabolic regulation‐immunotherapy (Figure 14A).[165] The combination of BAY‐876 and 2‐DG cut off the lactate production from the source through dual inhibition of glucose uptake and glycolysis process in tumor cells, thus effectively reversing the lactate‐related immunosuppressive TME to augment anti‐CTLA‐4‐based immunotherapy (Figure 14B).